Yes, Madam Chair, and I'm not sure that this is in order.
Actually, the one circulated piece of whatever we want to call it that was going to be a possible motion was with regard to the mandatory adverse event reporting. That is an issue that I wanted to bring forward. That was the one we talked about.
If it's any help, I would be glad to bring that forward as a topic of discussion, not as a motion, to be added to the list of other items that other members have for discussion. During our CDR study that was one thing that came up several times. We looked into prescription drugs and we looked into the regulatory review processes. Certainly, the adverse event reporting was something that we heard there were problems with. I wanted to put it forward as one item that would be there for consideration by this committee to study.
I would do that not in motion form but in terms of beginning the start of a list, if it's appropriate at this time.